Stock Movers Novo Soars on Obesity Pill Approval; Huntington Ingalls Rallies; Warner Bros
Dec 23, 2025
Novo Nordisk's shares surged after approval for an oral obesity pill, challenging rival Eli Lilly. Huntington Ingalls' stock rose following President Trump's announcement of a new 'Trump-class' battleship. In the entertainment realm, Warner Bros. Discovery gained traction as Larry Ellison backed a competing bid against Netflix for the company, spurring a heated takeover battle.
AI Snips
Chapters
Transcript
Episode notes
Novo Nordisk Gains Strategic Lead
- Novo Nordisk won US approval for a pill version of Wegovy, boosting its competitive position.
- The pill begins US sales in early January at about $150/month and gives Novo a head start over Eli Lilly.
Regaining Ground After A Tough Year
- Novo has lagged this year, down about 44% as Eli Lilly outperformed with injectables.
- The pill approval provides timely upside heading into year-end after Lilly's strong performance.
Defense Stocks React To Shipbuilding Plan
- Huntington Ingalls rallied after President Trump announced a new 'Trump-class' battleship and an FFX frigate.
- The ships are planned for Huntington Ingalls' Newport News yard, but production timing remains uncertain.